Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

NEXT STORY
Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
PREV STORY
Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer

AMES, Iowa, Nov. 14, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced ...

author_avatar
NASDAQ Market News

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company

-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and ...

author_avatar
NASDAQ Market News

Hemispherx Updates Stockholders, Highlighting Ampligen’s Role in Enhancing Immunotherapeutic Therapies

OCALA, Fla., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), ...

author_avatar
NASDAQ Market News